Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

600 results about "Effector cell" patented technology

An effector cell is any of various types of cell that actively responds to a stimulus and effects some change (brings it about).

Nano system for tumor radioimmunotherapy and preparation method and application thereof

The invention discloses a nano system for tumor radioimmunotherapy and a preparation method and application thereof, and belongs to the technical field of biological medicines.The system modifies bacteria outer membrane vesicles (OMVs) through engineering to enable the bacteria outer membrane vesicles to carry magnetite nanoparticles (Fe3O4NPs) and an ATR inhibitor VE822, the Fenton reaction activity of the Fe3O4NPs and the synergistic effect of the ATR inhibitor for inhibiting DNA damage repair are utilized, and the tumor radioimmunotherapy effect is improved. DNA damage is amplified, DNA damage reaction (DDR) is inhibited, generation of hydroxyl radicals (. OH) under radiation is enhanced, radiation resistance of tumor cells is reduced, immune reaction is reactivated, infiltration of effector T cells to tumors is improved, growth of mice tumors is remarkably inhibited, and an effective strategy is provided for tumor radioimmunotherapy.
Owner:ANHUI PROVINCIAL HOSPITAL

Therapeutic or prophylactic agent for xerophthalmia

The purpose of the present invention is to provide: a novel therapeutic or prophylactic agent for xerophthalmia; a therapeutic or prophylactic agent for graft-versus-host disease; a corneal epithelium wound healing promoter; a corneal invasive inflammatory cell inhibitor; or an inhibitor of differentiation of lymphocytes into effector T cells. The present invention provides: a therapeutic or prophylactic agent for xerophthalmia, a therapeutic or prophylactic agent for graft-versus-host disease, a corneal epithelial wound healing promoter, a corneal invasive inflammatory cell inhibitor, a tear amount maintenance agent, a corneal epithelial damage inhibitor, and a method for preparing the same, which comprises, as an active ingredient, a substance derived from a stem cell culture supernatant; a cell proliferation marker positive cell inhibitor, or an inhibitor of differentiation of lymphocytes to effector T cells.
Owner:U-FACTOR CO LTD +1

Method for detecting tumor killing activity of NK (Natural Killer) cells

The invention discloses a method for detecting tumor killing activity of NK (Natural Killer) cells. The method for detecting the tumor killing activity of the NK cells comprises the following steps: recovering and culturing K562 cells; preparing a target cell K562; preparing effector cells NK; the K562 cell suspension and the NK cell suspension are mixed according to the effect-target ratio to serve as an experimental group, the K562 cell suspension serves as a control group, after the experimental group and the control group are incubated in an incubator for a period of time, the cells are transferred into a centrifugal tube and cleaned with PBS, then PI dye liquor is added for incubation, and the cell suspension is obtained. Detecting the apoptosis rate of the K562 cells in the experimental group and the control group by adopting a flow cytometer, and calculating the tumor killing rate of the NK cells; the killing activity of the NK cells to the K562 tumor cells is evaluated through a CFSE / PI labeling method, operation is relatively simple, consumed time is short, sensitivity is high, repeatability is good, and the method has the advantages of being safe, efficient, economical, stable and the like and has good application value.
Owner:ALLCARE BIOMEDICAL DEV CO LTD

Application of parabacteroides dielsii SYSU-210 and metabolite thereof in cancer treatment

The invention belongs to the technical field of microorganisms, and particularly relates to application of parabacteroides dielsii SYSU-210 and metabolites thereof in cancer treatment. The parabacteroides dieldrii is a parabacteroides dieldrii SYSU-210 strain, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.32494, and the preservation date is November 04, 2024. According to the application disclosed by the invention, by carrying out anti-tumor treatment on tumor-bearing mice with colon cancer and breast cancer by using the single parabacteroides dieldrii SYSU-210 and a metabolite thereof, the screened SYSU-210 has a good treatment effect on both the colon cancer and the breast cancer, and effector T cell infiltration in tumors of the mice in a treatment group is remarkably increased; and when the compound is combined with an immunotherapy alpha PD-1 inhibitor or a chemotherapeutic drug oxaliplatin for use, the effect of synergistically enhancing the curative effect is shown.
Owner:SUN YAT SEN UNIV

Polypeptide for enhancing NK cell immune killing and inhibiting HSCs activation and application thereof

ActiveCN119101127AEnhance immune killing activityInhibitory activityPeptide/protein ingredientsDigestive systemPharmacy technologyPharmacy
The invention relates to the technical field of medicine and pharmacy, and discloses a polypeptide for enhancing NK cell immune killing and inhibiting HSCs activation and application of the polypeptide. The polypeptide obtained by the invention can cross vascular endothelium, can be used as a medium for connecting immune cells NK and hepatic fibrosis effector cells HSCs, and is beneficial to relieving hepatic fibrosis symptoms.
Owner:TIANJIN MEDICAL UNIV

Cells having solid tumor targeting backbone and use thereof

Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional genome editing that delivers improved or enhanced therapeutic effects. Further provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
Owner:FATE THERAPEUTICS INC

MRNA encoding checkpoint cancer vaccines and uses thereof

The present disclosure provides lipid nanoparticle (LNP) compositions comprising checkpoint cancer vaccines and uses thereof. The LNP compositions of the present disclosure comprise an mRNA therapeutic agent encoding a checkpoint cancer vaccine comprising IDO and a PD-L1 antigen peptide. The LNP compositions of the present disclosure can induce an immune response and stimulate T effector cells in vivo, and thus can be used to treat cancer.
Owner:MODERNATX INC

Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and CD16a

Multispecific proteins that bind NKp46 and specifically redirect effector cells to lyse a target cell of interest via multiple receptors are provided. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
Owner:INNATE PHARMA SA

Bioactive solution and application thereof

The invention relates to the technical field of medicine and pharmacy, and discloses a bioactive solution and application thereof, and the bioactive solution comprises a polypeptide with an amino acid sequence of SEQ ID NO.1 and a polypeptide with an amino acid sequence of SEQ ID NO.2. The bioactive solution obtained by the invention can cross vascular endothelium, can be used as a medium for connecting immune cells NK and hepatic fibrosis effector cells HSCs, and is beneficial to relieving hepatic fibrosis symptoms.
Owner:TIANJIN MEDICAL UNIV

Composition for inducing proliferation or accumulation of regulatory T cells

It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
Owner:THE UNIV OF TOKYO

Interleukin-2 variants and methods of uses thereof

The present invention relates to polypeptides which share primary sequence with human Interleukin 2 (IL-2), except for several amino acids that have been mutated. One panel of IL-2 variants comprise mutations with impressive manufacturability that preferentially promotes the proliferation, survival, activation and / or function of immunosuppressive regulatory T cells (Tregs) (Treg: CD4+CD25+FoxP3+) over effector T cells and Natural Killer Cells (NK). cells. Also includes therapeutic uses of such IL-2 selective agent, used alone, or in combination with immune modulating agents or disease-tissue targeting antibody, protein or peptide to treat Treg cell-deficiency, various autoimmune and inflammatory disorders, organ transplantation and graft-versus-host disease. In another aspect the present invention relates to pharmaceutical compositions comprising the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their selective modulating effect of the immune system on diseases like autoimmune and inflammatory disorders.
Owner:CUGENE INC

Kit and method for detecting inhibition condition of dust mite specific blocking antibody on basophilic granulocyte activation and application

The invention relates to a kit and a method for detecting inhibition of basophilic granulocyte activation by a dust mite specific blocking antibody and application of the kit and belongs to the technical field of biology. The kit for detecting the condition of inhibiting basophilic granulocyte activation by the dust mite specific blocking antibody contains basophilic granulocytes, a dust mite allergen and an anti-human CD63 antibody. According to the invention, the function of inhibiting effector cell activation by the dust mite specific blocking antibody is reflected by directly detecting the basophilic granulocyte activation condition. The method is simple, convenient and accurate to operate, is suitable for evaluating the dust mite allergen specific immunotherapy effect, and is beneficial to guiding clinical dust mite allergen specific immunotherapy. The ability of different types of dust mite specific blocking antibodies to inhibit dust mite activated basophilic granulocytes with the same or similar epitopes is evaluated, and the research on the cross reaction between dust mite antigen components is facilitated.
Owner:YANGJIANG PEOPLES HOSPITAL

ADCP biological activity detection method based on single luciferase

The invention discloses a monoluciferase-based ADCP biological activity detection method, which comprises the following steps: separating a mononuclear cell from a human peripheral blood mononuclear cell as an effector cell, phagocytizing a Raji cell transfected by Luciferase as a target cell by the mononuclear cell, acidifying and degrading the Raji cell in a phagocytic body, and degrading the Luciferase so as to attenuate a light-emitting signal, so that the ADCP biological activity is detected. The ADCP biological activity of the antibody therapeutic drug is accurately quantified by detecting the weakening of the light-emitting signal. According to the present invention, the method only needs to separate the mononuclear cells and perform Luciferase infection on the target cells, and only needs to add the luciferase substrate after the phagocytosis process, such that the luminescence value can be read by using the microplate reader, the operation process is simple, the steps are less, the time consumption is short, the high-throughput screening is achieved, and the new direction is provided for the ADCP detection.
Owner:NEOMAB BIOTECHNOLOGY CO LTD

Method and system for analyzing lung cancer brain metastasis organoid cell subpopulation and functional characteristics

The invention provides a method and system for analyzing lung cancer brain metastasis organoid cell subpopulation and functional characteristics, and the method comprises a series of steps: data quality control, batch effect removal, cell grouping, copy number variation inference, quasi-time sequence analysis, function enrichment analysis, and drug sensitivity analysis before and after radiotherapy. Single cell transcriptome sequencing data obtained after organoid culture is subjected to personalized analysis, heterogeneity of tumor cells and sensitivity of the tumor cells to drugs after radiotherapy are described, and the characteristics of all cell subgroups in the lung cancer brain metastasis organoid and the effect of the cell subgroups in the tumor microenvironment can be accurately analyzed; powerful support is provided for mechanism research and precise medicine of lung cancer brain metastasis.
Owner:SHANGHAI PULMONARY HOSPITAL (SHANGHAI OCCUPATIONAL DISEASE PREVENTION & CONTROL INSTITUTE)

Anaplastic lymphoma kinase (ALK) specific t cell receptors and methods of use thereof

The invention features polypeptides and / or transgenic effector cells including T cell receptors (TCRs) which specifically bind anaplastic lymphoma kinase (ALK) antigens or peptide sequences, and the use of such polypeptides and / or transgenic effector cells and TCRs specific to anaplastic lymphoma kinase (ALK) antigens or peptide sequences in compositions and methods for treating ALK-positive neoplasias such as Non-Small Cell Lung Cancers (NSCLCs).
Owner:CHILDRENS MEDICAL CENT CORP

SHP inhibitor compositions and uses for chimeric antigen receptor therapy

Compositions and methods for treating diseases associated with expression of a cancer associated antigen are disclosed. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, SHP inhibitory molecules, vectors encoding the same, and recombinant immune effector cells comprising the CARs and SHP inhibitory molecules. Methods of administering a genetically modified immune effector cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen and a SHP inhibitory polypeptide are also disclosed.
Owner:NOVARTIS AG +1

Ru (II) complex as well as preparation method and application thereof

The invention relates to the technical field of antitumor drugs, in particular to a Ru (II) complex and a preparation method and application thereof, and the Ru (II) complex has a structure as shown in a formula I. The ruthenium (II) complex has excellent anti-tumor activity, can induce tumor cells to generate ICD death, can be quickly positioned in an endoplasmic reticulum, causes the intracellular active oxygen level to rise, blocks the cell cycle in the S phase, and finally induces the tumor cells to generate pyroptosis. More importantly, MCF-7 cells can be caused to generate endoplasmic reticulum stress, so that an ICD effect is triggered, DC in tumor tissues is increased, chemotaxis of effector T cells in the tumor tissues is improved, and meanwhile, the number of Treg cells with an immunosuppression effect can be reduced, so that tumor immunity of an organism is activated. In addition, the Ru (II) complex can activate a cGAS-STING pathway, the proportion of CD8 + T cells is increased, and the anti-tumor immunocompetence is further improved.
Owner:GUANGDONG MEDICAL UNIV

Method for determining biological activity of recombinant human endostatin

The embodiment of the invention relates to a method for determining the biological activity of recombinant human endostatin. The method comprises the following steps: carrying out mixed culture on a subculture cell which is subjected to L929 cell culture subculture and is used as an effector cell and recombinant human endostatin to be detected; cracking the cells subjected to mixed culture to obtain a lysis solution; the method comprises the following steps of: preparing a lysate, measuring the absorbance of the lysate, performing mixed culture on the basis of a measured result, a human endostatin standard substance and effector cells, and obtaining the biological activity of the recombinant human endostatin to be measured by utilizing a relative biological activity method. The biological activity of the recombinant human endostatin to be detected can be obtained, and the detection result is reliable.
Owner:SHANDONG INST FOR FOOD & DRUG CONTROL

Orthopedic implant material with degradable time sequence as well as preparation method and application thereof

The invention relates to a time sequence degradable orthopedic implant material which comprises a base material and a biodegradable coating formed on the surface of the base material, the surface of the base material is provided with a nanocone array microstructure, the biodegradable coating takes a biodegradable polymer as a matrix and loads a metal element for promoting bone repair, and the metal element is a metal element for promoting bone repair. And the surface of the biodegradable coating is also connected with an anti-inflammatory active factor. According to the invention, grafted anti-inflammatory active factors are matched with the biodegradable coating loaded with metal elements for promoting bone repair, and the sequential active regulation and control of the biological effect of the micro-morphology on the surface of the base material cope with effector cells in different repair stages; the time sequence regulation and control on the macrophage inflammation phenotype and bone marrow mesenchymal stem cell osteogenic differentiation in different stages of bone repair are realized, so that each stage of bone tissue repair is matched, and bone repair and osseointegration are promoted.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI

SH1 homologous cluster fully human TSH receptor blocking monoclonal antibody group as well as preparation method and application of SH1 homologous cluster fully human TSH receptor blocking monoclonal antibody group

The invention discloses a group of blocking monoclonal antibodies of an SH1 homologous cluster fully human thyrotropin receptor (TSHR) (a TSH receptor, TSHR) as well as a preparation method and application of the blocking monoclonal antibodies of the SH1 homologous cluster fully human thyrotropin receptor (TSHR). The method comprises the following steps: sorting plasma cells and memory single B cells for specifically recognizing TSHR in peripheral blood of a patient with high TSH receptor blocking antibody (TBAb) titer by using flow cytometry, cloning antibody light and heavy chains in vitro and performing recombinant expression, and performing antibody property screening verification by using hTSHR-CHO cells. The blocking monoclonal antibody specifically targeting the human TSHR is obtained. The fully human TSH receptor blocking monoclonal antibody disclosed by the invention can be specifically combined with TSHR, and can effectively block signal transduction after the TSH is combined with the receptor; the synthesis and secretion of thyroid hormone are inhibited; expression and fibrosis of effector cell orbital fibroblasts TSHR for inhibiting thyroid-related eye diseases are remarkably relieved, and wide application prospects are achieved in treatment of Graves' diseases and diseases such as thyroid eye diseases caused by hyperthyroidism.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens

Provided herein are multispecific antibodies for redirecting T cells to cancers, that rely on binding of one antigen interacting portion of the antibody to a tumor-associated antigen or marker, such as epidermal growth factor receptor (EGFR), while a second antigen interacting portion can bind to an effector cell antigen on a T cell, such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
Owner:JANUX THERAPEUTICS INC

Dendritic cell albumin suspension, preparation method and application

The invention belongs to the technical field of immune effect drugs, and discloses a dendritic cell albumin suspension and a preparation method and application thereof.The preparation method of the dendritic cell albumin suspension includes the following steps that isolated mononuclear cells PBMC are collected, and matured DCs are cultured in a laminar flow purification laboratory; loading the multi-valence hepatitis B virus antigen epitope peptide on the DC; and the DC cell albumin suspension is prepared. The CTL immune effect excited by the DC can effectively remove HBV viruses in an integrated state in liver cells, so that the conditions of patients with hepatitis B and cirrhosis are reversed until HBV antigens are negative, and the conditions are relieved fundamentally; in the immune response excited by DC, the effector CTL cells immediately play a role in clearing HBV viruses, and the memory T lymphocytes play a role in clearing HBV viruses in vivo for a long time, so that the condition of hepatitis B is continuously reversed. Reagents used in the DC culture process are completely localized. The cost is greatly reduced and is obviously lower than that of foreign countries, and popularization is facilitated; china gets rid of the history of long-term dependence on imported anti-hepatitis B viruses.
Owner:SHAANXI XIANGSHAN CELL BIOTECHNOLOGY CO LTD

Method and composition for treating tumors

Provided in the present invention are a composition of immune effector cells and a treatment kit including the composition of immune effector cells, wherein the composition of immune effector cells comprises an initial dose of immune effector cells and a subsequent dose of immune effector cells.
Owner:CRAGE MEDICAL CO LTD

CHK36 homologous cluster fully human TSH receptor blocking monoclonal antibody group as well as preparation method and application thereof

The invention discloses a group of blocking monoclonal antibodies of a CHK36 homologous cluster fully human TSH receptor (TSHR) as well as a preparation method and application of the blocking monoclonal antibodies. The method comprises the following steps: sorting plasma cells and memory single B cells for specifically recognizing TSHR in peripheral blood of a patient with high TSH-blocking antibody (TBAb) titer by using flow cytometry, cloning antibody light and heavy chains in vitro and performing recombinant expression, and performing antibody property screening verification by using hTSHR-CHO cells, so as to obtain the TSHR-TBAb-TSHR-TBAb. The blocking monoclonal antibody specifically targeting the human TSHR is obtained. The fully human TSH receptor blocking monoclonal antibody disclosed by the invention can be specifically combined with TSHR, and can effectively block signal transduction after the TSH is combined with the receptor; the synthesis and secretion of thyroid hormone are inhibited; according to the present invention, with the application of the compound, the expression and the fibrosis of the effector cell orbit fibroblast TSHR inhibiting the thyroid-related eye disease can be significantly reduced, and the wide application prospect is provided in the treatment of Graves' disease (Graves' disease, GD) and diseases caused by hyperthyroidism, such as thyroid eye disease (thyroid eye disease, TED), and the like.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Broad-spectrum multi-antigen pan-coronavirus vaccine

Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen / LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.
Owner:RGT UNIV OF CALIFORNIA

Antigen-specific immune effector cells

Provided herein are methods for the production of antigen-specific effector T cells and NK cells from pluripotent stem cells which express a chimeric antigen receptor (CAR). Further provided herein are methods for the adoptive cell therapy by administering the effector T cells and / or NK cells provided herein.
Owner:FUJIFILM CELLULAR DYNAMICS INC

Application of CCR5hi innate immune memory cell in preparation of immunotherapy drug for treating sepsis

ActiveCN119896727AAntibacterial agentsAntipyreticBacterial lipoproteinTherapeutic effect
The invention relates to the technical field of biological medicines, particularly discloses an application of a CCR5hi innate immune memory cell in preparation of an immunotherapy drug for treating sepsis, and provides an innate immune memory cell CD45 + CD11b + Ly6G-Ly6C + CCR5hi mononuclear cell which is generated by induction training immunity of bacillus calmette guerin vaccine and bacterial lipoprotein and has a protection effect on sepsis. Through single cell sequencing analysis and functional verification, the cell subset characteristics of the sepsis are accurately identified, and the functional mechanism of the sepsis is clarified, so that the key blank of unclear effector cell identity and unclear action target in the prior art is filled, and a cellular theoretical basis and a technical scheme are provided for targeted immunotherapy of the sepsis; and a better treatment effect is expected to be achieved in clinical practice.
Owner:SOOCHOW UNIV AFFILIATED CHILDRENS HOSPITAL

Antibodies to ICOS

Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Combinations of anti-ICOS antibodies and other drugs for immunooncology.
Owner:KYMBA LIMITED

Bionic nano radiotherapy sensitizer as well as preparation method and application thereof

The invention discloses a bionic nano radiotherapy sensitizer as well as a preparation method and application thereof, and belongs to the field of tumor treatment. The bionic nano radiotherapy sensitizer comprises a radiotherapy sensitizing material and a nano-material, a small interfering RNA; the tumor cell coating wraps the radiotherapy sensitization material and the small interfering RNA; the near-infrared fluorescent dye is modified on the outer surface of the tumor cell coating. The sensitizer disclosed by the invention can be used for specifically recognizing homotype tumors, delivering the radiotherapy sensitizer after accurate targeting of the tumors, effectively enhancing intracellular radioactive ray energy deposition, improving the hypoxia state of tumor cells, sensitizing radiotherapy, silencing expression of target genes of the tumor cells and inhibiting negative immunoregulation, so that the anti-tumor immune response of effector T cells is enhanced, and the radiotherapy effect is improved. In addition, on the basis of the near-infrared fluorescent material, the in-vivo delivery process of the bionic nano radiotherapy sensitizer can be traced.
Owner:GENERAL HOSPITAL OF NUCLEAR IND